Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul;25(7):1869-1892.
doi: 10.1007/s12094-023-03189-3. Epub 2023 Apr 17.

Landscape of NcRNAs involved in drug resistance of breast cancer

Yujuan Kang  1
Affiliations
Review

Landscape of NcRNAs involved in drug resistance of breast cancer

Yujuan Kang. Clin Transl Oncol. 2023 Jul.

Abstract

Breast cancer (BC) leads to the most amounts of deaths among women. Chemo-, endocrine-, and targeted therapies are the mainstay drug treatments for BC in the clinic. However, drug resistance is a major obstacle for BC patients, and it leads to poor prognosis. Accumulating evidences suggested that noncoding RNAs (ncRNAs) are intricately linked to a wide range of pathological processes, including drug resistance. Till date, the correlation between drug resistance and ncRNAs is not completely understood in BC. Herein, we comprehensively summarized a dysregulated ncRNAs landscape that promotes or inhibits drug resistance in chemo-, endocrine-, and targeted BC therapies. Our review will pave way for the effective management of drug resistance by targeting oncogenic ncRNAs, which, in turn will promote drug sensitivity of BC in the future.

Keywords: ASOs; Breast cancer; Chemotherapy; Endocrine therapy; NcRNAs; Resistance; Targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
NcRNAs promote chemo-resistance
Fig. 2
Fig. 2
NcRNAs promote chemo-sensitivity
Fig. 3
Fig. 3
NcRNAs regulate response to endocrine therapy
Fig. 4
Fig. 4
NcRNAs regulate response to targeted therapy
Fig. 5
Fig. 5
Oncogenic ncRNAs regulate drug resistance in breast cancer
See this image and copyright information in PMC

References

    1. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomarkers Prev. 2016;25(25):16–27. doi: 10.1158/1055-9965.EPI-15-0578. - DOI - PubMed
    1. Bertos NR, Park M. Breast cancer - one term, many entities? J Clin Invest. 2011;121(121):3789–3796. doi: 10.1172/JCI57100. - DOI - PMC - PubMed
    1. Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 2004;40(40):2667–2675. doi: 10.1016/j.ejca.2004.08.021. - DOI - PubMed
    1. Amelio I., Bernassola F., Candi E., Emerging roles of long non-coding RNAs in breast cancer biology and management, Semin Cancer Biol. (2020). - PubMed
    1. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32(32):3744–52. doi: 10.1200/JCO.2014.55.5730. - DOI - PMC - PubMed